BF-222

BF-222 is a small molecule drug candidate being developed by Bullfrog AI Holdings for the treatment of glioblastoma and other high-grade gliomas. It is a proprietary formulation of the repurposed anthelmintic drug mebendazole, originally licensed from Johns Hopkins University. The formulation is enriched for a specific polymorph of mebendazole that demonstrates improved bioavailability and an enhanced ability to cross the blood-brain barrier compared to standard formulations. Mebendazole acts as a microtubule inhibitor by binding to tubulin, which disrupts spindle formation during mitosis and leads to cell cycle arrest and apoptosis in cancer cells. BF-222 has been evaluated in Phase I clinical trials where it was shown to be safe when used in combination with adjuvant temozolomide in patients with newly diagnosed high-grade gliomas.

Other names

mebendazole